These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38943034)

  • 41. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis: a meta-analysis of randomized controlled trials.
    Navalha DDP; Felix N; Nogueira A; Clemente M; Marinho AD; Ferreira ROM; Pasqualotto E; Dagostin CS; Pinto LCS; Fernandes GC
    Int Urol Nephrol; 2024 Jun; 56(6):2001-2010. PubMed ID: 38153665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
    Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
    Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
    Harel Z; Sholzberg M; Shah PS; Pavenski K; Harel S; Wald R; Bell CM; Perl J
    J Am Soc Nephrol; 2014 Mar; 25(3):431-42. PubMed ID: 24385595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
    Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation.
    Selvaraj V; Khan MS; Mufarrih SH; Kazimuddin M; Waheed MA; Tripathi A; Bavishi C; Hyder ON; Aronow HD; Saad M; Abbott JD
    Am J Cardiol; 2023 Aug; 201():260-267. PubMed ID: 37393728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulation in atrial fibrillation. A large real-world update.
    Bo M; Fumagalli S; Degli Esposti L; Perrone V; Dovizio M; Poli D; Marcucci R; Verdecchia P; Reboldi G; Lip GYH; Ungar A; Boccanelli A; Fumagalli C; Marchionni N;
    Eur J Intern Med; 2024 Mar; 121():88-94. PubMed ID: 37879969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis.
    Hu T; Li YH; Han WQ; Maduray K; Chen TS; Hao L; Zhong JQ
    Am J Cardiovasc Drugs; 2023 Nov; 23(6):683-694. PubMed ID: 37639201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis.
    Li Y; Wu S; Zhou J; Zhang J
    Thromb J; 2024 Apr; 22(1):40. PubMed ID: 38679736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease.
    Arnson Y; Hoshen M; Berliner-Sendrey A; Reges O; Balicer R; Leibowitz M; Avgil Tsadok M; Haim M
    Cardiology; 2020; 145(3):178-186. PubMed ID: 31955174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Souverein PC; van den Ham HA; Huerta C; Merino EM; Montero D; León-Muñoz LM; Schmiedl S; Heeke A; Rottenkolber M; Andersen M; Aakjaer M; De Bruin ML; Klungel OH; Gardarsdottir H
    Br J Clin Pharmacol; 2021 Mar; 87(3):988-1000. PubMed ID: 32627222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
    Mostaza JM; Suarez C; Cepeda JM; Manzano L; Sánchez D;
    BMC Cardiovasc Disord; 2021 Aug; 21(1):384. PubMed ID: 34372782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation.
    Abrahami D; Renoux C; Yin H; Fournier JP; Azoulay L
    Thromb Haemost; 2020 Oct; 120(10):1384-1394. PubMed ID: 32717756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
    Kooiman J; van Rein N; Spaans B; van Beers KA; Bank JR; van de Peppel WR; del Sol AI; Cannegieter SC; Rabelink TJ; Lip GY; Klok FA; Huisman MV
    PLoS One; 2014; 9(5):e94420. PubMed ID: 24817475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anticoagulation in patients with non-valvular atrial fibrillation (nvAF) and chronic kidney disease (CKD)].
    Zeymer U; Bonnemeier H; Wanner C
    Dtsch Med Wochenschr; 2019 Nov; 144(23):1642-1649. PubMed ID: 31752037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis.
    Troisi F; Guida P; Vitulano N; Quadrini F; Di Monaco A; Grimaldi M
    Int J Cardiol; 2023 May; 379():40-47. PubMed ID: 36907451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients.
    Iftimi AA; Rodríguez-Bernal CL; Peiró S; Bonanad S; Ferrero-Gregori A; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
    Clin Pharmacol Ther; 2022 Jan; 111(1):200-208. PubMed ID: 34242404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.